European Journal of Internal Medicine
Volume 19, Issue 5 , Pages 334-339 , July 2008

Prognostic significance of pleural fluid data in patients with malignant effusion

  • Silvia Bielsa

      Affiliations

    • Pleural Diseases Unit, Department of Internal Medicine, Arnau de Vilanova University Hospital, Institut de Recerca Biomèdica de Lleida, Lleida, Spain
    • ,
  • Antonieta Salud

      Affiliations

    • Medical Oncology Service, Arnau de Vilanova University Hospital, Institut de Recerca Biomèdica de Lleida, Lleida, Spain
    • ,
  • Montserrat Martínez

      Affiliations

    • Department of Biostatistics, Arnau de Vilanova University Hospital, Institut de Recerca Biomèdica de Lleida, Lleida, Spain
    • ,
  • Aureli Esquerda

      Affiliations

    • Department of Laboratory Medicine, Arnau de Vilanova University Hospital, Institut de Recerca Biomèdica de Lleida, Lleida, Spain
    • ,
  • Antonio Martín

      Affiliations

    • Medical Oncology Service, Arnau de Vilanova University Hospital, Institut de Recerca Biomèdica de Lleida, Lleida, Spain
    • ,
  • Francisco Rodríguez-Panadero

      Affiliations

    • Department of Respiratory Medicine, Virgen del Rocío University Hospital, Sevilla, Spain
    • ,
  • José M. Porcel

      Affiliations

    • Pleural Diseases Unit, Department of Internal Medicine, Arnau de Vilanova University Hospital, Institut de Recerca Biomèdica de Lleida, Lleida, Spain
    • Corresponding Author InformationCorresponding author. Department of Internal Medicine, University Hospital Arnau de Vilanova, Avda. Alcalde Rovira Roure 80, 25198 Lleida, Spain. Tel.: +34973705262.

Received 18 June 2007 ,Accepted 26 September 2007.

References 

  1. Gary-Lee YC, Light RW. Management of malignant pleural effusions. Respirology. 2004;9:148–156
  2. Antunes G, Neville E, Duffy J, Ali N. BTS guidelines for the management of malignant pleural effusions. Thorax. 2003;58(Suppl II):ii29–ii38
  3. Antony VB, Loddenkemper R, Astoul P, Boutin C, Goldstraw P, Hott J, et al. Management of malignant pleural effusions. Eur Respir J. 2001;18:402–419
  4. Burrows CM, Mathews C, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions. An assessment of the prognostic values of physiologic, morphologic and quality of life measures of extent of disease. Chest. 2000;117:73–78
  5. Good JT, Taryle DA, Sahn SA. The pathogenesis of low glucose, low pH malignant effusions. Am Rev Respir Dis. 1985;131:737–741
  6. Foresti V, Scolari N, Villa A, Parisio E, De Filippi G, Guareschi G. Malignant pleural effusions: meaning of pleural-fluid pH determination. Oncology. 1990;47:62–64
  7. Martínez-Moragón E, Aparicio J, Sanchis J, Menéndez R, Rogado MC, Sanchis F. Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration. 1998;65:108–113
  8. Jiménez D, Díaz G, Gil D, Cicero A, Pérez-Rodriguez E, Sueiro A, et al. Etiology and prognostic significance of massive pleural effusions. Respir Med. 2005;99:1183–1187
  9. Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusion. Chest. 2000;117:79–86
  10. Banerjee AK, Willets I, Robertson JF, Blamey RW. Pleural effusion in breast cancer: a review of the Nottingham experience. Eur J Surg Oncol. 1994;20:33–36
  11. Aelony Y, Yao JF. Prolonged survival after talc poudrage for malignant pleural mesothelioma: case series. Respirology. 2005;10:649–655
  12. Sahn SA, Good JT. Pleural fluid pH in malignant effusions. Diagnostic, prognostic and therapeutic implications. Ann Intern Med. 1988;107:345–349
  13. Sánchez-Armengol A, Rodríguez-Panadero F. Survival and talc pleurodesis in metastatic pleural carcinoma, revisited. Report of 125 cases. Chest. 1993;104:1482–1485
  14. Aelony Y, Yao JF, King RR. Prognostic value of pleural fluid pH in malignant epithelial mesothelioma after talc poudrage. Respiration. 2006;73:334–339
  15. Crnjac A, Sok M, Kamenik M. Impact of pleural effusion pH on the efficacy of thoracoscopic mechanical pleurodesis in patients with breast carcinoma. Eur J Cardiothorac Surg. 2004;26:432–436
  16. Bilaçeroglu S, Cagirici U, Perim K, Özacar R. Corynebacterium parvum pleurodesis and survival is not significantly influenced by pleural pH and glucose level. Monaldi Arch Chest Dis. 1998;53:14–22
  17. Romero-Romero B, Sánchez-Gutierrez C, Hernández-Martínez A, Martín-Juan J, Castillo J, Rodríguez-Panadero F. Mesotheliomas have a lower pleural pH and longer survival than metastatic carcinomas, and similar outcome of talc pleurodesis. [abstract] Am J Respir Crit Care Med. 2002;165:33S
  18. Heffner JE, Heffner JN, Brown LK. Multilevel and continuous pleural fluid pH likelihood ratios for evaluating malignant pleural effusions. Chest. 2003;123:1887–1894
  19. Goldstein LS, Mc Carthy K, Mehta AC, Arroliga AC. Is direct collection of pleural fluid into a heparinized syringe important for determination of pleural pH? A brief report. Chest. 1997;112:707–708
  20. Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer. 1980;45:2220–2224
  21. Al Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C, McMillan DC. Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer. 2006;94:227–230
  22. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dagg K, Scott HR. A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2005;92:1834–1836
  23. Deans DA, Wigmore SJ, Gilmour H, Paterson-Brown S, Ross JA, Fearon KC. Elevated tumour interleukin-1 beta is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer. Br J Cancer. 2006;95:1568–1575

PII: S0953-6205(07)00287-7

doi: 10.1016/j.ejim.2007.09.014

European Journal of Internal Medicine
Volume 19, Issue 5 , Pages 334-339 , July 2008

Article Tools